Reply to the letter regarding ‘Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study’

• Masatoshi Kudo,
• Kaoru Tsuchiya,
• Tatsuya Yamashita,
• Hironori Koga,
• Yuki Nakagawa,
• Masafumi Ikeda

Affiliations

Masatoshi Kudo

Kaoru Tsuchiya

Tatsuya Yamashita

Hironori Koga

Yuki Nakagawa

Masafumi Ikeda